CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents

@article{Yin2014CYP17IC,
  title={CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents},
  author={Lina Yin and Qingzhong Hu},
  journal={Nature Reviews Urology},
  year={2014},
  volume={11},
  pages={32-42}
}
  • Lina Yin, Qingzhong Hu
  • Published 2014
  • Medicine
  • Nature Reviews Urology
  • As the first in class steroid 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor, abiraterone acetate (of which the active metabolite is abiraterone) has been shown to improve overall survival in patients with castration-resistant prostate cancer (CRPC)—in those who are chemotherapy-naive and those previously treated with docetaxel. Furthermore, the clinical success of abiraterone demonstrated that CRPC, which has previously been regarded as an androgen-independent disease, is still driven, at… CONTINUE READING
    89 Citations
    Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
    • 21
    • PDF
    Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    • 17
    • PDF
    Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
    • 69
    • PDF
    Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1
    • 11
    • PDF
    In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug–drug interactions
    • 3
    Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen

    References

    SHOWING 1-10 OF 119 REFERENCES
    Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    • G. Attard, A. Reid, +16 authors J. D. de Bono
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 546
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
    • G. Attard, A. Reid, +13 authors J. D. de Bono
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2008
    • 788
    VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC).
    • 8
    Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.
    • S. Pisle, H. M. Pressler, +5 authors W. Figg
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2012
    • 5
    Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    • C. Ryan, M. Smith, +9 authors E. Small
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 353